Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EBIT (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed EBIT for 15 consecutive years, with -$189000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 96.37% year-over-year to -$189000.0, compared with a TTM value of -$4.7 million through Sep 2025, down 376.9%, and an annual FY2024 reading of $2.6 million, up 120.11% over the prior year.
  • EBIT was -$189000.0 for Q3 2025 at Fennec Pharmaceuticals, up from -$2.7 million in the prior quarter.
  • Across five years, EBIT topped out at $13.7 million in Q1 2024 and bottomed at -$6.1 million in Q4 2022.
  • Average EBIT over 5 years is -$2.4 million, with a median of -$3.9 million recorded in 2021.
  • Peak annual rise in EBIT hit 360.78% in 2024, while the deepest fall reached 411.5% in 2024.
  • Year by year, EBIT stood at -$4.2 million in 2021, then tumbled by 47.02% to -$6.1 million in 2022, then skyrocketed by 70.37% to -$1.8 million in 2023, then surged by 48.62% to -$934000.0 in 2024, then skyrocketed by 79.76% to -$189000.0 in 2025.
  • Business Quant data shows EBIT for FENC at -$189000.0 in Q3 2025, -$2.7 million in Q2 2025, and -$808000.0 in Q1 2025.